

Table SI. Baseline patient characteristics

Patients	<i>n</i> = 27 (%)
Age at the time of diagnosis, years (median), years	31.1
< 5, <i>n</i> (%)	3 (11)
6–15, <i>n</i> (%)	2 (7)
16–20, <i>n</i> (%)	0 (0)
21–40, <i>n</i> (%)	12 (44)
41–60, <i>n</i> (%)	7 (26)
> 60, <i>n</i> (%)	3 (11)
Sex ratio, female/male	22/5
Time from first symptom to diagnosis, months (median)	4.6
Autoimmune medical past ^a , <i>n</i> (%)	11 (40)
Lupus	6 (22)
Antiphospholipid syndrome	4 (14)
Alopecia areata	1 (4)
Granulomatous mastitis	2 (7)
Autoimmune cytopaenia	1 (4)
Erythema nodosum	1 (4)
Panniculitis medical past ^b , <i>n</i> (%)	6 (22)
LP	2 (7)
LP followed by histiocytic and cytophagic panniculitis	2 (7)
Histiocytic and cytophagic panniculitis	2 (7)
Trigger factors, <i>n</i> (%)	6 (22)
Pregnancy	3 (11)
Infectious diseases	3 (11)

^aSum of autoimmune subset is superior to 11 as some patients could associate 2 or more entities. ^bPatients with lupus panniculitis (LP) are also included with patients with lupus in the previous section.

Table SII. Clinical presentation

Symptoms ^a	<i>n</i> = 25
Cutaneous lesions size ^b , <i>n</i> (%)	
1–5 cm	9 (64)
5–10 cm	3 (22)
>10 cm	2 (14)
Morphology of cutaneous lesions, <i>n</i> (%)	
Nodules	21 (84)
Infiltrative lesions, plaques	7 (28)
Ulceration or necrosis	5 (20)
Number of cutaneous lesions, <i>n</i> (%)	
Isolated lesion	2 (8)
Multiple lesions	23 (92)
Localization of cutaneous lesions, <i>n</i> (%)	
Upper limb	15 (60)
Lower limb	14 (56)
Trunk	8 (32)
Back	6 (24)
Face	9 (36)
General symptoms, <i>n</i> (%)	18 (72)
Fever	13 (52)
Asthenia	13 (52)
Weight loss	9 (36)
Extracutaneous localizations, <i>n</i> (%)	6 (24)
Lymph node enlargement	4 (16)
Splenomegaly	5 (20)
Hepatomegaly	5 (20)

^aTwo patients had insufficient descriptions of lesions and symptoms, and were excluded. ^bThis information was available only for 14 patients.

Table SIII. Biological abnormalities

Parameters	n (%)
Lymphopaenia (< 1,400/mm ³)	13/15 (87)
β2-microglobulinaemia (> 2.5 mg/l)	10/12 (83)
C-reactive protein elevation	12/18 (66)
Lactate dehydrogenase (> 2 N)	15/23 (65)
Ferritin (> 300 µg/l)	10/16 (62)
Hypertriglyceridaemia (> 1.8 mmol/l)	8/15 (53)
Erythrocyte sedimentation rate elevation	7/13 (53)
Elevated liver enzyme	10/20 (50)
Haemophagocytic syndrome ^a	10/27 (37)
Liver cholestasis	5/17 (29)
Hypoalbuminaemia	3/13 (23)
Auto-antibodies	13/20 (65)
Anti-nuclear antibody	12/20 (60)
Anti-cardiolipin	7/20 (35)
Anti-DNA	7/20 (35)
Anti-Ro	2/20 (10)
Angiotensin converting enzyme elevation	2/20 (10)
Positive Coombs test	2/20 (10)
Positive Dixon test	1/20 (5)
Anti-tissues	1/20 (5)
Decreased complement activity	3/11 (27)

^aHemophagocytic syndrome was defined according to HLH-2004 criteria (25).

For each parameter, the same absolute number of patients can be associated with different percentages as it depends of the total number of patients, which have been tested for it.

Table SIV. Immunophenotypical characteristics of subcutaneous panniculitis-like T-cell lymphoma

Markers	n (%)
CD3	27/27 (100)
CD5	21/26 (81)
CD8	27/27 (100)
Granzyme B	27/27 (100)
TIA1	15/18 (83)
CD56	0/27 (0)
CD30	1/27 (3)
Epstein Barr encoding region	0/16 (0)
P53	4/22 (18)
Ki67	
High	11/18 (61)
Intermediate	3/18 (17)
Low	4/18 (22)
MxA	
Negative	7/17 (41)
< 25% of cells	7/17 (41)
> 25% of cells	3/17 (18)
CD123 and CD303	
Negative	10/17 (59)
Isolated cells plasmacytoid dendritic cells	7/17 (41)
Clusters of plasmacytoid dendritic cells	0/17 (0)
αβ phenotype	27/27 (100)
βF1staining	17/22 (77)
Monoclonal β T cell receptor rearrangement	17/19 (89)